Distribution and characterization of anandamide amidohydrolase in mouse brain and liver. 1998

K Watanabe, and H Ogi, and S Nakamura, and Y Kayano, and T Matsunaga, and H Yoshimura, and I Yamamoto
Department of Hygienic Chemistry, Faculty of Pharmaceutical Sciences, Hokuriku University, Kanazawa, Japan.

Anandamide (N-Arachidonoylethanolamine) amidohydrolase catalyzing hydrolysis of anandamide was characterized in mice. The enzymatic activity was highest in the liver, followed by the brain and testis. Negligible activity was found in heart, lung and spleen. The activity in brain and liver was mainly localized in the microsomal fractions. Kinetic experiments demonstrated that Km (microM) and Vmax (nmol/min/mg protein) for the brain microsomes were 9.3 and 2.58, respectively, while those for the hepatic microsomes were 180 and 18.9, respectively. The activity in the microsomes from the liver and brain was markedly inhibited by Cu2+, Hg2+, Se4+, phenylmethylsulfonylfluoride and sodium dodecylsulfate. Brain but not hepatic microsomal enzyme activity was inhibited by delta9-tetrahydrocannabinol, cannabidiol and cannabinol. Kinetic parameters demonstrated that the inhibition by the cannabinoids was competitive in nature. Relatively high distribution of the enzyme activity in brain suggests an importance of the enzyme in the central nervous system to regulate the neuromodulatory fatty-acid amides.

UI MeSH Term Description Entries
D008099 Liver A large lobed glandular organ in the abdomen of vertebrates that is responsible for detoxification, metabolism, synthesis and storage of various substances. Livers
D008297 Male Males
D008670 Metals Electropositive chemical elements characterized by ductility, malleability, luster, and conductance of heat and electricity. They can replace the hydrogen of an acid and form bases with hydroxyl radicals. (Grant & Hackh's Chemical Dictionary, 5th ed) Metal
D008862 Microsomes, Liver Closed vesicles of fragmented endoplasmic reticulum created when liver cells or tissue are disrupted by homogenization. They may be smooth or rough. Liver Microsomes,Liver Microsome,Microsome, Liver
D009928 Organ Specificity Characteristic restricted to a particular organ of the body, such as a cell type, metabolic response or expression of a particular protein or antigen. Tissue Specificity,Organ Specificities,Specificities, Organ,Specificities, Tissue,Specificity, Organ,Specificity, Tissue,Tissue Specificities
D001921 Brain The part of CENTRAL NERVOUS SYSTEM that is contained within the skull (CRANIUM). Arising from the NEURAL TUBE, the embryonic brain is comprised of three major parts including PROSENCEPHALON (the forebrain); MESENCEPHALON (the midbrain); and RHOMBENCEPHALON (the hindbrain). The developed brain consists of CEREBRUM; CEREBELLUM; and other structures in the BRAIN STEM. Encephalon
D002186 Cannabinoids Compounds having the cannabinoid structure. They were originally extracted from Cannabis sativa L. The most pharmacologically active constituents are TETRAHYDROCANNABINOL; CANNABINOL; and CANNABIDIOL. Cannabinoid
D004791 Enzyme Inhibitors Compounds or agents that combine with an enzyme in such a manner as to prevent the normal substrate-enzyme combination and the catalytic reaction. Enzyme Inhibitor,Inhibitor, Enzyme,Inhibitors, Enzyme
D000581 Amidohydrolases Any member of the class of enzymes that catalyze the cleavage of amide bonds and result in the addition of water to the resulting molecules. Amidases,Amidohydrolase
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia

Related Publications

K Watanabe, and H Ogi, and S Nakamura, and Y Kayano, and T Matsunaga, and H Yoshimura, and I Yamamoto
January 1997, Advances in experimental medicine and biology,
K Watanabe, and H Ogi, and S Nakamura, and Y Kayano, and T Matsunaga, and H Yoshimura, and I Yamamoto
March 1995, The Journal of biological chemistry,
K Watanabe, and H Ogi, and S Nakamura, and Y Kayano, and T Matsunaga, and H Yoshimura, and I Yamamoto
February 1997, Biochemical and biophysical research communications,
K Watanabe, and H Ogi, and S Nakamura, and Y Kayano, and T Matsunaga, and H Yoshimura, and I Yamamoto
May 1999, Journal of medicinal chemistry,
K Watanabe, and H Ogi, and S Nakamura, and Y Kayano, and T Matsunaga, and H Yoshimura, and I Yamamoto
March 1999, Journal of medicinal chemistry,
K Watanabe, and H Ogi, and S Nakamura, and Y Kayano, and T Matsunaga, and H Yoshimura, and I Yamamoto
January 1997, Advances in experimental medicine and biology,
K Watanabe, and H Ogi, and S Nakamura, and Y Kayano, and T Matsunaga, and H Yoshimura, and I Yamamoto
August 1997, Biochimica et biophysica acta,
K Watanabe, and H Ogi, and S Nakamura, and Y Kayano, and T Matsunaga, and H Yoshimura, and I Yamamoto
April 2000, Prostaglandins & other lipid mediators,
K Watanabe, and H Ogi, and S Nakamura, and Y Kayano, and T Matsunaga, and H Yoshimura, and I Yamamoto
January 2002, Advances in experimental medicine and biology,
K Watanabe, and H Ogi, and S Nakamura, and Y Kayano, and T Matsunaga, and H Yoshimura, and I Yamamoto
November 2001, FEBS letters,
Copied contents to your clipboard!